Acute Bacterial Skin and Skin Structure Infections (ABSSSI) refer to bacterial skin infections that involve the skin and associated soft tissues or structures such as major cutaneous abscesses, surgical and traumatic wound infections, and cellulitis or erysipelas. Common causative pathogens include Staphylococcus aureus and Streptococcus pyogenes. If left untreated, these infections can turn serious with complications like sepsis or necrotizing fasciitis. The global Acute Bacterial Skin and Skin Structure Infections Market is estimated to be valued at US$ 3,466.6 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: Rising resistance to currently used antibiotics poses a serious threat for the treatment of ABSSSI. According to a report by WHO, antibiotic resistance is one of the biggest threats to global health, food security, and development today. The overuse and misuse of antibiotics are the main drivers of resistance. As antibiotic options become more limited, conventional antibiotic therapies may become ineffective against ABSSSI-causing pathogens. This is expected to drive increased adoption of newer targeted treatment options and boost growth of the ABSSSI market during the forecast period.
SWOT Analysis
Strength: The acute bacterial skin and skin structure infections market has a large patient pool due to rising number of bacterial skin infections globally. Growing prevalence of diabetes and obesity which increases the risk of these infections also boosts market growth.
Weakness: Low diagnosis rates in developing regions due to lack of awareness poses challenges to market growth. Limited treatment options also constrain market potential.
Opportunity: Increasing demand for advanced treatment options present an opportunity for companies to invest in R&D and introduce novel therapies. Emerging economies with improving healthcare infrastructures offer new growth avenues.
Threats: Presence of alternative treatments using antibiotics poses competition to drug makers. Stringent regulations for drug approvals also increases costs of development and market entry.
Key Takeaways
The global acute bacterial skin and skin structure infections market is expected to witness high growth.
Regional analysis focused on North America dominates currently owing to strong healthcare systems and high treatment rates. The Asia Pacific region is anticipated to grow at fastest pace due to growing healthcare infrastructure and demand for cost-effective treatment options in developing nations.
Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it